法国诊断公司Novacyt S.A.宣布，已达成协议以850万澳元（约合550万美元）的对价收购澳大利亚诊断企业Southern Cross Diagnostics。
此次收购旨在强化Novacyt在亚太地区的市场布局。交易完成后，Southern Cross Diagnostics现有的核心管理团队，包括首席执行官在内，将悉数留任，以确保业务平稳过渡和持续运营。
法国诊断公司Novacyt S.A.宣布，已达成协议以850万澳元（约合550万美元）的对价收购澳大利亚诊断企业Southern Cross Diagnostics。
此次收购旨在强化Novacyt在亚太地区的市场布局。交易完成后，Southern Cross Diagnostics现有的核心管理团队，包括首席执行官在内，将悉数留任，以确保业务平稳过渡和持续运营。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.